← 홈

ADC

505개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 505개
ADCBiologicAmgenbiodistributionPhase 2

Sotorasib (Sotorasib)

Colorectal Cancer; Resectable Colorectal Carcinoma · Locally Advanced Lung Non-Small Cell Car

#LocallyAdvancedLungNon-SmallCell#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 0%임상시험 51상태 RECRUITING
ADCBiologicAstraZenecaderuxtecan or sacituzumab g…Phase 2

Capivasertib (Capivasertib)

Metastatic Breast Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 56.5%임상시험 50상태 RECRUITING
ADCBiologicSWOG Cancer Research Networkderuxtecan (T-DXd) and tyro…Phase 3

Cyclin-Dependent Kinase 4 Inhibitor (Cyclin-Dependent Kinase 4 Inhibitor)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 57.98%임상시험 50상태 RECRUITING
ADCBiologicAstex Pharmaceuticals, Inc.Phase 2

Decitabine and Cedazuridine (Decitabine and Cedazuridine)

Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 0%임상시험 50상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…Phase 2

Itacitinib (Itacitinib)

Breast Cancer; Gastrointestinal Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 93%임상시험 48상태 ACTIVE
ADCBiologicPharmaMarderuxtecan in patients with…Phase 3

Lurbinectedin (Lurbinectedin)

Small-cell Lung Cancer; Relapsed Small Cell Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 40.7%임상시험 48상태 RECRUITING
ADCBiologicStrata OncologyPhase 2

encorafenib + binimetinib (encorafenib + binimetinib)

Cancer; Advanced Solid Tumor · Cancer

#Cancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 66.7%임상시험 48상태 DISCONTINUED
ADCBiologicSWOG Cancer Research NetworkPhase 3

Cyclin-Dependent Kinase 6 Inhibitor (Cyclin-Dependent Kinase 6 Inhibitor)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 24%임상시험 47상태 RECRUITING
ADCBiologicValerio TherapeuticsPhase 3

Dexrazoxane Hydrochloride (Dexrazoxane Hydrochloride)

Cardiac Toxicity; Inflammatory Breast Cancer · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 78.6%임상시험 47상태 RECRUITING
ADCBiologicAstellasVedotin Plus Pembrolizumab …Phase 3

EV/P (enfortumab vedotin and pembrolizumab, enfortumab vedotin and pembrolizumab (EV/P))

Advanced Bladder Cancer · Advanced Bladder Cancer

#AdvancedBladderCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 15.6%임상시험 47상태 RECRUITING
ADCBiologicPfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 75.3%임상시험 46상태 DISCONTINUED
ADCBiologicCanadian Cancer Trials Groupvedotin, a monoclonal antib…Phase 2

Adavosertib (Adavosertib)

Prostate Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 66.7%임상시험 45상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…Phase 2

Pemigatinib (Pemigatinib)

Breast Cancer; Gastrointestinal Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 37%임상시험 45상태 ACTIVE
ADCBiologicOHSU Knight Cancer InstitutePhase 1

Enasidenib (Enasidenib)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 73.5%임상시험 43상태 DISCONTINUED
ADCBiologicEMD Serono Research & Developme…Phase 3

M7824 (M7824)

Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 62.5%임상시험 43상태 DISCONTINUED
ADCBiologicCancer Research UKvedotin, and venetoclax dem…Phase 3

Entrectinib (Entrectinib)

Haematological Malignancy; Solid Tumour · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 11.5%임상시험 42상태 DISCONTINUED
ADCBiologicGileadgovitecan-hziy (Trodelvy), …Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan-hziy)

Metastatic Urothelial Cancer · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 34.3%임상시험 42상태 RECRUITING
ADCBiologicAstraZenecadeliveryPhase 3

Ceralasertib (Ceralasertib)

Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 19%임상시험 41상태 RECRUITING
ADCBiologicMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
임상시험 41상태 RECRUITING
ADCBiologicCanadian Cancer Trials GroupPhase 2

Savolitinib (Savolitinib)

Prostate Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57.1%임상시험 41상태 RECRUITING

7 / 26 페이지

← 이전다음 →